ストックスクリーナーアプリを入手
5.58
0.89%
-0.05
前日終値:
$5.63
開ける：
$5.63
24時間の取引高:
3.27M
Relative Volume:
1.40
時価総額：
$903.63M
収益：
$181.41M
当期純損益:
$-59.56M
株価収益率:
-13.29
EPS:
-0.42
ネットキャッシュフロー:
$-38.83M
1週間 パフォーマンス:
-3.96%
1か月 パフォーマンス:
+48.40%
6か月 パフォーマンス:
+94.43%
1年 パフォーマンス:
+152.49%
1日の値動き範囲:
$5.51
$5.70
1週間の範囲:
$5.51
$6.07
52週間の値動き範囲:
$1.69
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
名前
Xeris Biopharma Holdings Inc
セクター
電話
844-445-5704
住所
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.58 | 903.63M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2023-08-28 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Craig Hallum | Buy |
| 2021-11-17 | 開始されました | SVB Leerink | Outperform |
| 2021-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-02-18 | 開始されました | Piper Sandler | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Leerink Partners | Outperform |
| 2018-07-16 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Xeris Biopharma Holdings Inc (XERS) 最新ニュース
Xeris Pharmaceuticals Announces Board Changes with New Appointment - TipRanks
Xeris Announces Changes To Its Board Of Directors - Marketscreener.com
Xeris Biopharma reshuffles board, appoints new director - Investing.com India
Xeris Biopharma reshuffles board, appoints new director By Investing.com - Investing.com Australia
Ex-AstraZeneca CFO Joins Xeris Board: Strategic Move Adds 30 Years Pharma Expertise - StockTitan
Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? - Insider Monkey
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp - Defense World
Don't Ignore The Insider Selling In Xeris Biopharma Holdings - Simply Wall St
Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why - Defense World
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock - Investing.com Australia
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock By Investing.com - Investing.com South Africa
Xeris Pharmaceuticals stock hits 52-week high at $5.54 - Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $5.54 By Investing.com - Investing.com South Africa
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy? - Defense World
Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris enters a whole new market for one of its main pharma offerings - Crain's Chicago Business
Is XERS Stock a Good Buy in 2025? Key Insights for Investors - Stocks Telegraph
12 Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent - Investing.com Australia
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - BioSpace
Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent By Investing.com - Investing.com South Africa
Breakthrough FDA Approval: Xeris' Novel Glucagon Solution Transforms Radiologic Diagnostics - StockTitan
Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator (NASDAQ:XERS) - Seeking Alpha
Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34% - Simply Wall St
Xeris BiopharmaPossibly the best Pharma Stock - MSN
Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92 - Defense World
Will Xeris Biopharma's Financial Transformation Reach New Heights In 2025? - RTTNews
Xeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025 - Markets Insider
What Are Expectations For Xeris Biopharma Holdings Inc (NASDAQ: XERS) In The Short Term? - Stocks Register
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript - Insider Monkey
Analysts Issue Forecasts for Xeris Biopharma Q1 Earnings - Defense World
Piper Sandler Reaffirms Neutral Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World
HC Wainwright Reaffirms Buy Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World
Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA
Principal Financial Group Inc. Grows Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Rhumbline Advisers Purchases 7,408 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highli - GuruFocus.com
Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook - TipRanks
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In - MSN
Xeris Biopharma Holdings Inc. (XERS) reports earnings - Quartz
Xeris Biopharma Holdings, Inc. SEC 10-K Report - TradingView
Xeris Biopharma: Q4 Earnings Snapshot - CT Insider
Navigating XERS Stock: Xeris Biopharma Holdings Inc Journey - The InvestChronicle
Earnings call transcript: Xeris Pharmaceuticals Q4 2024 beats EPS forecast, stock surges By Investing.com - Investing.com South Africa
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance - BioSpace
Xeris Biopharma Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):